Generic Name and Formulations:
Carboprost (as tromethamine salt) 250mcg/mL; soln for IM inj; contains benzyl alcohol.
Indications for HEMABATE:
For aborting pregnancy between the 13th and 20th weeks of gestation in the following conditions related to second trimester abortion: 1) failure of expulsion of the fetus during the course of treatment by another method; 2) premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3) requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4) inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. For the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management.
Give by deep IM inj. Abortion: 250mcg; subsequent doses of 250mcg should be given at 1.5–3.5 hour intervals depending on uterine response. Optional test dose (100mcg) may be given initially. Dose may be increased to 500mcg if uterine contractility is judged to be inadequate after several doses of 250mcg. Max total dose: 12mg; continuous administration for >2 days not recommended. Refractory postpartum uterine bleeding: initially 250mcg once, may give additional doses at intervals of 15–90 mins if necessary. Max total dose: 2mg (8 doses).
Acute pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease.
Should only be used by trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities. Not indicated if fetus in utero has reached stage of viability. History of asthma, hypo- or hypertension, cardiovascular, renal, or hepatic disease, anemia, jaundice, diabetes, epilepsy. Compromised (scarred) uteri. Chorioamnionitis. Pregnancy (Cat.C).
Concomitant other oxytocic agents: not recommended.
Vomiting, diarrhea, nausea, flushing, chills, headache, pain, breast tenderness; transient pyrexia (see full labeling re: PGEs induced pyrexia vs. endometritis pyrexia), others.
Ampules (1mL)—1, 10
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Weight Gain After Quitting Smoking May Increase Risk for T2D
- In Teens, Young Adults, High BMI May Hurt Cardiovascular Health
- Obesity Paradox Affects Type 2 Diabetes Mortality Rates
- Bi-Directional Association Observed Between Obstructive Sleep Apnea and Diabetes
- Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis